One of the most difficult health care decisions that women and their doctors have to make today concerns postmenopausal hormone replacement therapy (HRT)[1]. Menopause, defined as the cessation of periods for 6 months or more, is just one event during the natural biological process of ovarian atrophy that begins as early as the mid-thirties. It is accompanied by varying degrees of short term symptoms such as hot flushes, night sweats, mood swings and insomnia, to long term problems that determine frailty, durability and death of women, viz., urogenital atrophy, osteoporosis, coronary artery disease, stroke and cancer. Most of these changes are attributed to ovarian deficiency, so it makes sense to replace deficient hormones to sustain premenopausal youth and quality of life, to satisfy the eternal human desire for good health and immortality [2]. Currently, an average woman lives more than a third of her life after the menopause. This is also the phase in her life when the risk of cardiovascular disease, cancer, osteoporosis and cognitive decline are highest. Although women live longer than men, they are reported to have a poorer health related quality of life [3]. Does HRT eradicate or attenuate these problems? Usually HRT is (or means) treatment with oestrogen alone or oestrogen in combination with progesterone. HRT nearly doubles the circulating hormonal concentration in a postmenopausal woman, without reaching that of a premenopausal woman [2]. Data from a national survey in the USA in 1997 revealed that 45% of women born between 1897 and 1950 took HRT at least for 1 month and 20% continued for 5 years or more [4]. In …